World's largest registry launches for deadly heart tumor
NCT ID NCT06715579
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This international registry will gather data from 500 people diagnosed with cardiac angiosarcoma, a rare and aggressive heart cancer. Researchers aim to identify risk factors and evaluate which treatments—like surgery, chemo, or immunotherapy—work best. The goal is to create evidence-based guidelines to improve survival and care for future patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors identify better treatments and create standard care guidelines for this rare heart cancer.
- What could go wrong
- This is an observational registry, not a treatment trial. It collects existing data and won't directly test new therapies, so improvements may take years to emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yeolyan Hematology and Oncology Center
RECRUITINGYerevan, 0014, Armenia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••